Erwinia asparaginase in pediatric acute lymphoblastic leukemia

Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials

(2011) A. Willer et al.   BLOOD

Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia

(2011) J. D. Kawedia et al.   BLOOD

The cross-reactivity of anti-asparaginase antibodies against different l-asparaginase preparations

(2009) Beata Zalewska-Szewczyk et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia

(2009) J C Panetta et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000)

(2009) L B Silverman et al.   LEUKEMIA

Acute lymphoblastic leukaemia

(2008) Ching-Hon Pui et al.   LANCET

Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study

(2008) I M Appel et al.   LEUKEMIA